Physician profile
Daniel A Gozzi
NPI 1316931413
$1,186,949.85
in general payments reported to CMS, 2019-2025
66 companies · $232K in 2025
The $232K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144K · 2020: $98K · 2021: $146K · 2022: $189K · 2023: $133K · 2024: $245K · 2025: $232K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $464K · Travel and Lodging: $124K · Food and Beverage: $18K · Consulting Fee: $2,425 · Honoraria: $988 · Education: $30.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $464,250.95 |
| Travel and Lodging | $123,954.71 |
| Food and Beverage | $17,979.83 |
| Consulting Fee | $2,425.00 |
| Honoraria | $987.50 |
| Education | $30.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $532,510.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $357,829.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $216,575.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $29,427.86 | 2019-2025 | Farxiga |
| Abbvie INC. | $20,186.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,337.06 | 2019-2025 | Jardiance |
| Mannkind Corporation | $5,002.91 | 2019-2025 | Afrezza |
| Amneal Pharmaceuticals LLC | $1,856.10 | 2019-2025 | Unithroid |
| Genzyme Corporation | $1,606.50 | 2025 | |
| Allergan, INC. | $1,524.46 | 2019 | |
| Xeris Pharmaceuticals, INC. | $1,220.38 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Cequr Corporation | $1,095.69 | 2022-2025 | Cequr Simplicity |
| Corcept Therapeutics | $1,078.77 | 2019-2025 | Korlym |
| Abbott Laboratories | $835.64 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Afinion 2 |
| Amgen INC. | $511.38 | 2019-2025 | Evenity, Prolia, Tepezza |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $439.11 | 2021-2025 | |
| Insulet Corporation | $288.96 | 2019-2025 | Omnipod |
| Dexcom, INC. | $276.15 | 2021-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $274.51 | 2019-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $270.62 | 2023-2024 | |
| Beta Bionics, INC. | $227.77 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Intuity Medical INC | $227.55 | 2022 | |
| Madrigal Pharmaceuticals | $218.80 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $213.64 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $195.57 | 2020-2025 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $194.10 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $165.65 | 2019-2022 | |
| Amarin Pharma, INC. | $151.33 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $142.91 | 2025 | Yorvipath |
| Zealand Pharma US, INC. | $130.98 | 2021-2022 | |
| Antares Pharma, INC. | $130.73 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Alexion Pharmaceuticals, INC. | $129.53 | 2022-2025 | Strensiq |
| Medtronic, INC. | $121.14 | 2021-2025 | Minimed 780g, Inceptiv |
| Lifescan, INC. | $101.31 | 2022-2023 | |
| Senseonics, Incorporated | $100.00 | 2019 | |
| Acerus Pharmaceuticals Corporation | $94.60 | 2020-2021 | |
| Shire North American Group INC | $92.17 | 2019 | |
| Ascensia Diabetes Care US INC. | $85.10 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $78.03 | 2019-2020 | |
| Becton, Dickinson and Company | $76.85 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $73.61 | 2020-2021 | |
| Clarus Therapeutics INC. | $67.83 | 2021 | |
| Esperion Therapeutics, INC. | $62.16 | 2021-2025 | Nexletol |
| Ibsa Pharma INC. | $59.73 | 2021-2024 | Tirosint, Licart, Licart |
| Embecta Corp. | $52.35 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Eusa Pharma (US) LLC | $51.71 | 2022 | |
| Tolmar, INC. | $48.98 | 2024-2025 | Jatenzo |
| Vivus LLC | $48.68 | 2019 | |
| Horizon Therapeutics Plc | $46.28 | 2023 | Tepezza |
| Pfizer INC. | $41.09 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $37.39 | 2019 | |
| Averitas Pharma INC. | $32.82 | 2025 | Qutenza |
| Nevro Corp. | $30.28 | 2023 | Senza |
| Coloplast Corp | $28.19 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $27.02 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $25.69 | 2024 | Crysvita |
| Eisai INC. | $25.65 | 2019 | |
| Chiesi USA, INC. | $23.86 | 2025 | Mycapssa |
| Medtronic Minimed, INC. | $23.09 | 2019 | |
| Neurocrine Biosciences, INC. | $21.56 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $21.54 | 2024 | |
| Sequel Med Tech, LLC | $18.58 | 2025 | Twiist |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.59 | 2021 | |
| Valeritas, INC. | $14.26 | 2019 | |
| Gilead Sciences, INC. | $12.35 | 2019 | |
| Companion Medical, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.